Abstract CT019: A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Evaluation of efficacy in KRAS mutated NSCLC
Matthew G. Krebs
◽
Rajiv Shinde
◽
Rozana Abdul Rahman
◽
Rafael Grochot
◽
Martin Little
◽
...